Fampyra and T cell Immunity in Multiple Sclerosis; a study of the Famp
FATIMS - Fampyra and T cell Immunity in Multiple Sclerosis; a study of the Fampyra induced immunomodulatory T cell responses in MS
What it found
The trial ended early for another reason (see below).
What was tested
Treatment tested
- Dalfampridine
Voltage-gated potassium channel blocker
What it measured
Main measures
Frequency of T cell subsets (CD4, CD8, Treg), frequency of TEM (CCR7-CD62LlowCD45RA-) and TCM (CCR7+CD62LhiCD45RA-), activation state of these five T cell subsets (CD25, HLA-DR, CD69), and their intracellular cytokine expression (IL-2, IFN-, IL-4, IL-5, IL-10, IL-17)
Immune response
Other measures (1)
Not applicaple
Who could take part
MS (type not specified)
Show the full criteria
Inclusion criteria
Inclusion: MS patients treated with fampridine for at least one year. Exclusion: None, if fulfilling the inclusion criteria.
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To compare ex vivo T cell functions in 20 MS patients on fampridine for >1 year to 20 clinically matched MS patients without fampridine treatment.
Loading reviews and guidelines…
Related trials
- Dalfampridine Combined With Physical Therapy for Mobility Impairment i
Phase 3 · Recruiting
Still running
- Clemastine Fumarate as Remyelinating Treatment in Internuclear Ophthal
Phase 3 · Stopped early
Stopped: not working
- New strategies for diagnostic, therapeutic and clinical care in neurol
Phase 4 · Status unknown
No results found
- Muscle Strain in Multiple Sclerosis Patients Measured by Ultrasound Sp
Not a drug-phase study · Completed
Paper found, not read
- Fampridine in MS Patients: A Cognition, Fatigue, Depression and Qualit
Completed
Paper found, not read
- Effects of dalfampridine on mobility in the context of daily life
Phase 4 · Completed
No results found
History
Started
Aug 2013